Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Flu vaccine selection

  • News

Executive Summary

Vaccines & Related Biological Products Advisory Committee postpones until mid-March selection of influenza A H3N2 vaccine strain for 2003-2004 flu season pending further analysis of new virus strains. Current vaccine strain, A/Panama/2007/99, has been ineffective at inhibiting recent strains marked by altered amino acid sequence, FDA and CDC reps said during Feb. 20 meeting. FDA committee is expected to hold teleconference March 17 or 18 on strain selection, at which time the panel also could hear data about occurrence of avian influenza virus (A H5N1) in Hong Kong. Committee voted to retain current A H1N1 (New Caledonia/20/99) and B (Hong Kong/330/2001 and 1434/02) strains...

Table

View full table

Tags:
Latest Headlines

EU & South Korea Sign Deal On Exchange Of Confidential Information

Recent And Upcoming FDA Advisory Committee Meetings

Mismatch Between Growing Vaccine Pipeline and CDC’s ACIP Capacity

Keeping Track: Two Breakthrough Oncologics, Another Antibiotic Clear US FDA Along With Pfizer’s Hemophilia B Gene Therapy

See All
UsernamePublicRestriction

Register

PS041313

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By